Oppenheimer Lowers Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $15.00

Inovio Pharmaceuticals (NASDAQ:INO) had its target price dropped by research analysts at Oppenheimer from $33.00 to $15.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target indicates a potential upside of 252.11% from the stock’s current price.

Separately, Royal Bank of Canada dropped their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research note on Friday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Inovio Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $40.00.

Inovio Pharmaceuticals Stock Performance

Shares of INO stock opened at $4.26 on Monday. The company has a market capitalization of $110.59 million, a price-to-earnings ratio of -1.18 and a beta of 0.83. The company has a 50-day simple moving average of $5.75 and a 200 day simple moving average of $8.14. Inovio Pharmaceuticals has a 52 week low of $4.20 and a 52 week high of $14.75.

Institutional Trading of Inovio Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at approximately $661,000. Signature Estate & Investment Advisors LLC acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at approximately $88,000. Rhumbline Advisers raised its position in shares of Inovio Pharmaceuticals by 5,943.0% in the 2nd quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 37,857 shares in the last quarter. American Century Companies Inc. raised its position in shares of Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 12,100 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at approximately $184,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.